Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| LifeMD, Inc.LFMD · Entity 6521 | Director | December 15, 2022 | December 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
LifeMD, Inc.
Report date December 15, 2022 · Filed December 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,000 |
Reported balance
After 2022-12-15 transaction · row 1
1 source rowRow 1 · 2022-12-15 · Grant · Acquired 75,000 · Balance 75,000 F1: Pursuant to the Company's 2020 Equity and Incentive Plan, as amended, the Director received a one-time grant of 75,000 restricted shares, with 37,500 shares vesting immediately and the remaining 37,500 shares vesting on December 15, 2024. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2027-12-15 | Direct | 37,500 |
Reported balance
After 2022-12-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-15 · Grant · Acquired 37,500 · Balance 37,500 F2: The option vests on December 15, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Company's 2020 Equity and Incentive Plan, as amended, the Director received a one-time grant of 75,000 restricted shares, with 37,500 shares vesting immediately and the remaining 37,500 shares vesting on December 15, 2024.
F2: The option vests on December 15, 2024.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Imprivata Inc
Report date September 16, 2016 · Filed September 20, 2016
Section 16 reporting ended · disclosed 2016-09-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-16 transaction · row 1
1 source rowRow 1 · 2016-09-16 · Disposition to issuer · Disposed 639 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger between the Issuer, Project Brady Merger Sub, Inc. and Project Brady Holdings, LLC (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were converted into the right to receive $19.25 per share in cash and, when so converted automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.05 · Expires 2021-09-30 | Direct | 0 |
Reported balance
After 2016-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-16 · Other · Disposed 70,000 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among Imprivata, Inc., Project Brady Merger Sub, Inc., and Project Brady Holdings, LLC, dated July 13, 2016, each unvested Company Common Stock Option shall immediately vest and become exercisable immediately prior to the Closing. At the Effective Time, each Company Common Stock Option having a per share exercise price less than $19.25 shall be cancelled for the right to receive in cash an amount per share equal to $19.25 less the exercise price. F4: Stock Options held under 2014 Non-Qualified Stock Agreement. |
| Restricted Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-09-30 | Direct | 0 |
Reported balance
After 2016-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-16 · Other · Disposed 1,914 · Balance 0 F3: Pursuant to the terms of the Agreement and Plan of Merger by and among Imprivata, Inc., Project Brady Merger Sub, Inc., and Project Brady Holdings, LLC, dated July 13, 2016, each restricted stock unit that is outstanding as of the Effective Time shall immediately accelerate in full in connection with the transaction and in consideration of the right to receive $19.25 per restricted stock unit. F5: Restricted Stock Units held under 2014 Restricted Stock Unit Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger between the Issuer, Project Brady Merger Sub, Inc. and Project Brady Holdings, LLC (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were converted into the right to receive $19.25 per share in cash and, when so converted automatically cancelled.
F2: Pursuant to the terms of the Agreement and Plan of Merger by and among Imprivata, Inc., Project Brady Merger Sub, Inc., and Project Brady Holdings, LLC, dated July 13, 2016, each unvested Company Common Stock Option shall immediately vest and become exercisable immediately prior to the Closing. At the Effective Time, each Company Common Stock Option having a per share exercise price less than $19.25 shall be cancelled for the right to receive in cash an amount per share equal to $19.25 less the exercise price.
F3: Pursuant to the terms of the Agreement and Plan of Merger by and among Imprivata, Inc., Project Brady Merger Sub, Inc., and Project Brady Holdings, LLC, dated July 13, 2016, each restricted stock unit that is outstanding as of the Effective Time shall immediately accelerate in full in connection with the transaction and in consideration of the right to receive $19.25 per restricted stock unit.
F4: Stock Options held under 2014 Non-Qualified Stock Agreement.
F5: Restricted Stock Units held under 2014 Restricted Stock Unit Agreement.
NAVIGANT CONSULTING INC
Report date October 11, 2019 · Filed October 16, 2019
Section 16 reporting ended · disclosed 2019-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-11 transaction · row 1
1 source rowRow 1 · 2019-10-11 · Disposition to issuer · Disposed 9,394 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 2, 2019, by and between the registrant and Guidehouse LLP ("Parent"), a Delaware limited liability partnership and Isaac Merger Sub, Inc. ("Merger Sub"), effective as of the effective time of the merger of Merger Sub with and into the registrant (the "Merger"), these shares of registrant common stock were canceled and converted to the right to receive $28 in cash per share (the "Merger Consideration"). This includes 5,462 restricted share units subject to time-based vesting conditions previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 2, 2019, by and between the registrant and Guidehouse LLP ("Parent"), a Delaware limited liability partnership and Isaac Merger Sub, Inc. ("Merger Sub"), effective as of the effective time of the merger of Merger Sub with and into the registrant (the "Merger"), these shares of registrant common stock were canceled and converted to the right to receive $28 in cash per share (the "Merger Consideration"). This includes 5,462 restricted share units subject to time-based vesting conditions previously reported.
WELLCARE HEALTH PLANS, INC.
Report date January 23, 2020 · Filed January 27, 2020
Section 16 reporting ended · disclosed 2020-01-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 1
1 source rowRow 1 · 2020-01-23 · Disposition to issuer · Disposed 1,512 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated March 26, 2019, by and among WellCare Health Plans, Inc. ("WellCare"), Centene Corporation ("Centene"), Wellington Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Centene ("Merger Sub I"), Wellington Merger Sub II, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Centene ("Merger Sub II" and, together with Merger Sub I, "Merger Subs"), pursuant to which Merger Sub I merged with and into WellCare on January 23, 2020 (the "Effective Time"). Upon the Effective Time, each outstanding share of WCG common stock and each outstanding restricted stock unit held by a non-employee director was converted into the right to receive (i) $120.000 in cash and (ii) 3.38 validly issued, fully paid and non assessable shares of Centene's common stock, par value $0.001 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated March 26, 2019, by and among WellCare Health Plans, Inc. ("WellCare"), Centene Corporation ("Centene"), Wellington Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Centene ("Merger Sub I"), Wellington Merger Sub II, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Centene ("Merger Sub II" and, together with Merger Sub I, "Merger Subs"), pursuant to which Merger Sub I merged with and into WellCare on January 23, 2020 (the "Effective Time"). Upon the Effective Time, each outstanding share of WCG common stock and each outstanding restricted stock unit held by a non-employee director was converted into the right to receive (i) $120.000 in cash and (ii) 3.38 validly issued, fully paid and non assessable shares of Centene's common stock, par value $0.001 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2033 Filed Jun 8, 2023 20:52 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 16,532 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0000950170-23-027046 · ownership.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,532 Underlying: Common Stock · 16,532 shares Expires 2023-06-06 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 19,676 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0001193125-26-259526 · ownership.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,676 Underlying: Common Stock · 19,676 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 33,662 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0000950170-25-083056 · ownership.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,662 Underlying: Common Stock · 33,662 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:42 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 23,114 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0000950170-24-070768 · ownership.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,114 Underlying: Common Stock · 23,114 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| December 15, 2022 Filed Dec 23, 2022 17:44 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001362118-22-000073 · primary_doc.xml · derivative · entry 2 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2027-12-15 F2 · derivative.exercise_date: The option vests on December 15, 2024. Read SEC document |
| December 15, 2022 Filed Dec 23, 2022 17:44 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001362118-22-000073 · primary_doc.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · price: Pursuant to the Company's 2020 Equity and Incentive Plan, as amended, the Director received a one-time grant of 75,000 restricted shares, with 37,500 shares vesting immediately and the remaining 37,500 shares vesting on December 15, 2024. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 10,391 | $0.00 Strike: $55.58 | $0.00 |
DisclosureSEC source: 0000899243-22-030269 · doc4.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,391 Underlying: Common Stock · 10,391 shares Expires 2032-09-01 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:53 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 3,126 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023465 · doc4.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,126 Underlying: Common Stock · 3,126 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| January 10, 2021 Filed Jan 11, 2021 22:26 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 11,609 | $0.00 Strike: $101.67 | $0.00 |
DisclosureSEC source: 0000899243-21-001351 · doc4.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,609 Underlying: Common Stock · 11,609 shares Expires 2031-01-09 F1 · derivative.exercise_date: The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant, January 10, 2021 and in equal monthly installments as to the remainder of the shares for two years thereafter. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 22:02 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Disposition to issuerCommon Stock | 1,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-001567 · doc1.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated March 26, 2019, by and among WellCare Health Plans, Inc. ("WellCare"), Centene Corporation ("Centene"), Wellington Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Centene ("Merger Sub I"), Wellington Merger Sub II, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Centene ("Merger Sub II" and, together with Merger Sub I, "Merger Subs"), pursuant to which Merger Sub I merged with and into WellCare on January 23, 2020 (the "Effective Time"). Upon the Effective Time, each outstanding share of WCG common stock and each outstanding restricted stock unit held by a non-employee director was converted into the right to receive (i) $120.000 in cash and (ii) 3.38 validly issued, fully paid and non assessable shares of Centene's common stock, par value $0.001 per share. Read SEC document |
| October 11, 2019 Filed Oct 16, 2019 15:35 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | Disposition to issuerCommon Stock | 9,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-053266 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 2, 2019, by and between the registrant and Guidehouse LLP ("Parent"), a Delaware limited liability partnership and Isaac Merger Sub, Inc. ("Merger Sub"), effective as of the effective time of the merger of Merger Sub with and into the registrant (the "Merger"), these shares of registrant common stock were canceled and converted to the right to receive $28 in cash per share (the "Merger Consideration"). This includes 5,462 restricted share units subject to time-based vesting conditions previously reported. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 14:19 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | GiftCommon Stock | 4,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-052993 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,394 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 12:41 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | GrantCommon Stock | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049780 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,317 F1 · kind: Grant of Restricted Stock Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect the issuer's payment of a cash dividend. Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 16:39 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | GrantCommon Stock | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037714 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,307 F1 · kind: Grant of Restricted Stock Units (RSUs) pursuant to the anti-dilution provisions of previously granted RSU awards, to reflect the issuer's payment of a cash dividend. Read SEC document |
| May 22, 2019 Filed May 23, 2019 20:17 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Exercise / conversionRestricted Stock Units · Derivative | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011974 · doc1.xml · derivative · entry 3 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F4 · derivative.exercise_date: The restricted stock units vested in full on May 22, 2019. Vested shares are delivered to the Reporting Person upon vest. F4 · derivative.expiration_date: The restricted stock units vested in full on May 22, 2019. Vested shares are delivered to the Reporting Person upon vest. Read SEC document |
| May 22, 2019 Filed May 23, 2019 20:17 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | GrantCommon Stock | 665 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011974 · doc1.xml · nonDerivative · entry 2 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,512 F2 · kind: Represents restricted stock units granted to the Reporting Person on May 22, 2019 and vest in full on the earlier of May 22, 2020 and the date of the Registrant's next annual meeting of stockholders. Vested shares will be delivered to the Reporting Person upon vest. Read SEC document |
| May 22, 2019 Filed May 23, 2019 20:17 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | Exercise / conversionCommon Stock | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011974 · doc1.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of restricted stock units granted to the Reporting Person on May 23, 2018. Read SEC document |
| May 14, 2019 Filed May 15, 2019 15:46 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | GrantCommon Stock | 5,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029950 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,295 Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:26 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | GrantCommon Stock | 4,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038556 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,855 Read SEC document |
| May 23, 2018 Filed May 24, 2018 20:44 UTC | WELLCARE HEALTH PLANS, INC. WCG · Entity 152183 | GrantRestricted Stock Units · Derivative | 847 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025530 · doc1.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847 Underlying: Common Stock · 847 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of WCG common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of May 23, 2019 and the date of the Registrant's next annual meeting of stockholders. Shares will be delivered to the reporting person upon vest. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of May 23, 2019 and the date of the Registrant's next annual meeting of stockholders. Shares will be delivered to the reporting person upon vest. Read SEC document |
| October 24, 2017 Filed Oct 26, 2017 17:35 UTC | NAVIGANT CONSULTING INC NCI · Entity 154427 | GrantCommon Stock | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-058061 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,932 Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 10:16 UTC | Imprivata Inc IMPR · Entity 182190 | OtherRestricted Stock Options · Derivative | 1,914 | $19.25 Strike: $0.00 | $36,844.50 |
DisclosureSEC source: 0000899243-16-029313 · doc4.xml · derivative · entry 3 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,914 shares Expires 2021-09-30 F3 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among Imprivata, Inc., Project Brady Merger Sub, Inc., and Project Brady Holdings, LLC, dated July 13, 2016, each restricted stock unit that is outstanding as of the Effective Time shall immediately accelerate in full in connection with the transaction and in consideration of the right to receive $19.25 per restricted stock unit. F5 · shares: Restricted Stock Units held under 2014 Restricted Stock Unit Agreement. Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 10:16 UTC | Imprivata Inc IMPR · Entity 182190 | OtherStock Option (Right to Buy) · Derivative | 70,000 | $8.20 Strike: $11.05 | $574,000.00 |
DisclosureSEC source: 0000899243-16-029313 · doc4.xml · derivative · entry 2 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2021-09-30 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among Imprivata, Inc., Project Brady Merger Sub, Inc., and Project Brady Holdings, LLC, dated July 13, 2016, each unvested Company Common Stock Option shall immediately vest and become exercisable immediately prior to the Closing. At the Effective Time, each Company Common Stock Option having a per share exercise price less than $19.25 shall be cancelled for the right to receive in cash an amount per share equal to $19.25 less the exercise price. F4 · shares: Stock Options held under 2014 Non-Qualified Stock Agreement. Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 10:16 UTC | Imprivata Inc IMPR · Entity 182190 | Disposition to issuerCommon Stock | 639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-029313 · doc4.xml · nonDerivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger between the Issuer, Project Brady Merger Sub, Inc. and Project Brady Holdings, LLC (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were converted into the right to receive $19.25 per share in cash and, when so converted automatically cancelled. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.